Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
EML4-ALK is a chimeric oncoprotein formed by the fusion of the EML4 gene with the ALK kinase domain. This fusion protein is primarily associated with non-small cell lung cancer (NSCLC), where it disrupts normal cellular signaling pathways, leading to uncontrolled cell growth and proliferation. The discovery of EML4-ALK as a driver mutation in NSCLC has significantly advanced the understanding of cancer biology and therapeutic development. EML4-ALK rearrangements are a rare but significant genetic alteration in NSCLC, accounting for approximately 1-2% of all lung cancer cases. These rearrangements are often detected through next-generation sequencing (NGS) and are considered a biomarker for targeted therapy with ALK inhibitors. The presence of EML4-ALK mutations can also influence the efficacy of other targeted therapies, such as EGFR tyrosine kinase inhibitors (TKIs), highlighting the importance of comprehensive genetic analysis in clinical practice.
ALK inhibitors are a class of small molecule drugs designed to target the ALK kinase domain, thereby inhibiting the abnormal signaling pathways driven by EML4-ALK fusion proteins. Some notable ALK inhibitors include crizotinib, alectinib and ceritinib, which have shown promising results in treating ALK-positive NSCLC patients. However, resistance to these inhibitors can develop due to mutations in the ALK kinase domain, necessitating the development of next-generation inhibitors with broader specificity.
BaF3 cells, derived from mouse pro-B cells, are widely used in biological research due to their dependence on IL-3 for growth and proliferation. By introducing specific kinase genes, BaF3 cells can be transformed into IL-3-independent cell lines, making them ideal for evaluating the efficacy of kinase inhibitors. The BaF3 cell lines expressing EML4-ALK and ALK fusion variants represent a powerful tool for researchers and pharmaceutical companies working on targeted therapies for ALK-positive cancers.
Creative Biogene offers a series of BaF3 cell lines which are engineered to stably express EML4-ALK as well as various ALK fusion variants. With our comprehensive validation services, stock availability, and expert support, we are committed to accelerating your research and driving innovation in cancer treatment.
1. qPCR Analysis of Gene Expression Level
2. Inhibitor IC50 Assay
3. Mycoplasma Detection
| MycoAlert Mycoplasma Detection Data | ||||
| Luminescence | A Value | B Value | B/A ratio | Result |
| Negative Control | 2864 | 838 | 0.29260 | / |
| Positive Control | 18114 | 1202330 | 66.37573 | / |
| BaF3-Human-EML4-ALK-G1202R-G1269A | 9930 | 7923 | 0.79789 | Negative/- |
| BaF3-Human-EML4-ALK-V1180L | 20208 | 12308 | 0.59116 | Negative/- |
4. Cell Morphology
 |  |
| BaF3-Human-EML4-ALK-G1202R-G1269A (4X) | BaF3-Human-EML4-ALK-G1202R-G1269A (10X) |
 |  |
| BaF3-Human-EML4-ALK-V1180L(4X) | BaF3-Human-EML4-ALK-V1180L(10X) |
Copyright © Creative Biogene. All rights reserved.